StockData
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL) income statement

AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.59−0.08 (-11.39%)

Close on Nov 20, 2026Market cap $54.83MP/E –Yield –

Anavex Life Sciences Corp. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-43.1%

Financial strength

Current ratio
–
Debt to equity
–
Debt to assets
–
Cash to current liabilities
–

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.49
Dividend yield
–

See a number that looks wrong?